Current biomarker studies on immunotherapy of HCC mainly include tumor genomic features, PD-L1 expression, tumor mutation burden, and microsatellite instability (Harding et al., 2019; Muhammed et al., 2022). This evidence concerns the gene CD274 and neoplasm.